Scott Tagawa, MD, MS, Weill Cornell Medicine, New York City, NY, provides an overview of recent research targeting prostate-specific membrane antigen (PSMA) in metastatic castration-resistant prostate cancer (mCRPC) at ASCO GU 2021. He describes the evaluation of circulating tumor cell (CTC) count as a prognostic biomarker in mCRPC following PSMA-targeted radionucleotide therapy (TRT), as well as a pilot study investigating unlabeled J591, an anti-PSMA antibody, in men with mCRPC and unfavorable CTC counts. A first-in-human phase I/II dose-escalation study (NCT04506567) of fractionated and multiple dose 225Ac-J591 is also currently underway in men with progressive mCRPC. This interview took place during the 2021 Genitourinary Cancers Symposium.

свернуть